HDAC9 and leiomyosarcoma: As the upregulation of class I HDACs has been reported in leiomyosarcoma (LMS)17 and computational analyses have identified HDACs as potential synthetic lethal targets in LMS,28 we then screened the HDAC inhibitor library across a panel of four LMS cell lines (Figure 3A).